CJC-1295 DAC 2 mg/ml 2 ml |

About CJC-1295 DAC | HilmaBiocare

CJC-1295 DAC - Hilma Biocare

CJC-1295 DAC is a long-acting peptide that functions as a growth hormone–releasing hormone (GHRH) analog. The “DAC” (drug affinity complex) modification extends its activity by increasing binding to circulating proteins, which may prolong its effect compared with shorter-acting GHRH peptides. In non-clinical contexts, it is discussed as a growth hormone secretagogue intended to support more sustained stimulation of endogenous growth hormone release. Regulatory status and approved use vary by country.

General Overview

Class: GHRH analog / growth hormone secretagogue (long-acting peptide)
Structure: CJC-1295 with DAC modification
Context of use: Research/medical context depends on jurisdiction; endocrine modulation under professional oversight where applicable

Potentially Observed Effects
(based on pharmacological mechanism and non-clinical reports)

Increased pulsatile growth hormone secretion over an extended period in responsive individuals
Secondary changes in IGF-1 depending on dose, duration, and individual response
Possible effects on recovery-related processes via GH/IGF-1 signaling (individual variation)
Changes in body composition reported by some users (strongly influenced by diet and training)

Safety Information

CJC-1295 DAC may be associated with endocrine and metabolic side effects. Reported reactions can include fluid retention, fatigue/weakness, and changes in glucose regulation in susceptible individuals. As with other hormone-modulating peptides, inappropriate or unsupervised use may disrupt normal endocrine balance. Individual responses vary.

Disclaimer: This text is provided for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Always comply with the laws of your country and consult qualified medical professionals.